Christopher Breder

Dr Christopher Breder is a physician-scientist with extensive experience in both the pharmaceutical industry and the U.S. Food and Drug Administration (FDA), spanning drug development, regulatory affairs, and clinical research across neurology, psychiatry and rare diseases.

As a Medical Officer at the FDA (2009-2019), he contributed to the review of numerous INDs and new drug and biologic application approvals in neurology, anesthesiology and rare diseases. In industry, he has held senior clinical development and strategic leadership roles at Sunovion Pharmaceuticals, Supernus Pharmaceuticals and Bristol Myers Squibb, overseeing programmes from early-stage development through approval and life-cycle management.

He currently works as a Strategic Consultant, advising biotechnology, investment, and legal organizations on clinical, regulatory, and scientific strategy.

With his dual perspective from the FDA and as an executive in drug development, he provides strategic insight into clinical development, regulatory strategy and life-cycle management of novel therapies in neuroscience and rare diseases.

Dr Breder holds an M.D. and Ph.D. from the University of Chicago.